Curaxys has developed a downstream technological platform on the basis of its own laboratory data, using the most advanced techniques successfully applied in the biotechnological and biopharmaceutical industries.

This platform is compromise of a sequence of well-defined procedures, where most of the parameters are clearly defined, and some others will be specifically adapted to each product. The platform also includes several critical points, such as the speed, the output, and the escalation of the process, as well as the purity, robustness, and reliability of the final product, among other point that remain to be adjusted as required by the physical and chemical properties of the product.

Our technological platform, CuraMab®, is mainly focused on the purification of monoclonal antibodies and fragments of antibodies. In addition to this, Curaxys has established its own downstream department, with staff  who are highly specialised in the purification of:

  • Recombinant proteins
  • Native proteins
  • Fusion proteins
  • Vaccines

To ensure that the biopharmaceutical character of each product of Curaxys remains, every step of these procedures is carried out according to the most strict GMP policy.

Curaxys has the capacity to purify and produce biomolecules, either at laboratory, pilot floor, or industrial level.

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

Latest News

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice